Unidad de Investigación en Modelos y Mecanismos

Publicaciones destacadas
David Ruano, José A. López-Martín, Lucas Moreno, Álvaro Lassaletta, Francisco Bautista, Maitane Andión, Carmen Hernández, África González-Murillo, Gustavo Melen, Ramón Alemany, Luis Madero, Javier García-Castro, Manuel Ramírez First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors Mol Ther. 2020 Apr 8; 28(4): 1033–1042.
David Ruano, José A. López-Martín, Lucas Moreno, Álvaro Lassaletta, Francisco Bautista, Maitane Andión, Carmen Hernández, África González-Murillo, Gustavo Melen, Ramón Alemany, Luis Madero, Javier García-Castro, Manuel Ramírez First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors Mol Ther. 2020 Apr 8; 28(4): 1033–1042.
PUBMED DOIThomas GP Grünewald, Marta Alonso, Sofia Avnet, Ana Banito, Stefan Burdach, Florencia Cidre‐Aranaz,Gemma Di Pompo, Martin Distel, Heathcliff Dorado‐Garcia, Javier Garcia‐Castro, Laura González‐González, Agamemnon E Grigoriadis, Merve Kasan, Christian Koelsche, Manuela Krumbholz, Fernando Lecanda, Silvia Lemma, Dario L Longo, Claudia Madrigal‐Esquivel, Álvaro Morales‐Molina, Julian Musa, Shunya Ohmura, Benjamin Ory, Miguel Pereira‐Silva, Francesca Perut, Rene Rodriguez, Carolin Seeling, Nada Al Shaaili, Shabnam Shaabani, Kristina Shiavone, Snehadri Sinha, Eleni M Tomazou, Marcel Trautmann, Maria Vela,Yvonne MH Versleijen‐Jonkers, Julia Visgauss, Marta Zalacain, Sebastian J Schober, Andrej Lissat, William R English, Nicola Baldini, Dominique Heymann. Sarcoma treatment in the era of molecular medicine EMBO Mol Med 2020; 12(11):e11131.
Thomas GP Grünewald, Marta Alonso, Sofia Avnet, Ana Banito, Stefan Burdach, Florencia Cidre‐Aranaz,Gemma Di Pompo, Martin Distel, Heathcliff Dorado‐Garcia, Javier Garcia‐Castro, Laura González‐González, Agamemnon E Grigoriadis, Merve Kasan, Christian Koelsche, Manuela Krumbholz, Fernando Lecanda, Silvia Lemma, Dario L Longo, Claudia Madrigal‐Esquivel, Álvaro Morales‐Molina, Julian Musa, Shunya Ohmura, Benjamin Ory, Miguel Pereira‐Silva, Francesca Perut, Rene Rodriguez, Carolin Seeling, Nada Al Shaaili, Shabnam Shaabani, Kristina Shiavone, Snehadri Sinha, Eleni M Tomazou, Marcel Trautmann, Maria Vela,Yvonne MH Versleijen‐Jonkers, Julia Visgauss, Marta Zalacain, Sebastian J Schober, Andrej Lissat, William R English, Nicola Baldini, Dominique Heymann. Sarcoma treatment in the era of molecular medicine EMBO Mol Med 2020; 12(11):e11131.
PUBMED DOIAlvaro Morales-Molina, Miguel Ángel Rodríguez-Milla, Alicia Gimenez-Sanchez, Ana Judith Perisé-Barrios, Javier García-Castro. Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models Cancers 2020 Jul; 12(7): 1920.
Alvaro Morales-Molina, Miguel Ángel Rodríguez-Milla, Alicia Gimenez-Sanchez, Ana Judith Perisé-Barrios, Javier García-Castro. Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models Cancers 2020 Jul; 12(7): 1920.
PUBMED DOIAna Gómez, David Sardón, Teresa Cejalvo, Fernando Vázquez, Javier García-Castro, Ana Judith Perisé-Barrios. Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy Molecular Therapy: Oncolytics Vol. 18 September 2020: 525-534.
Ana Gómez, David Sardón, Teresa Cejalvo, Fernando Vázquez, Javier García-Castro, Ana Judith Perisé-Barrios. Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy Molecular Therapy: Oncolytics Vol. 18 September 2020: 525-534.
PUBMED DOIA personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBioMedicine. (2024) 102:105090
Rey V, Tornín J, Alba-Linares JJ, Robledo C, Murillo D, Rodríguez A, Gallego B, Huergo C, Viera C, Braña A, Astudillo A, Heymann D, Szuhai K, Bovée JVMG, Fernández AF, Fraga MF, Alonso J, Rodríguez R.
PUBMEDNAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences.
Perez-Luz S, Matamala N, Gomez-Mariano G, Janciauskiene S, Martínez-Delgado B. NAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences. Biomedicines. 2023 Jul 12;11(7).
PUBMED DOILoss of Serpina1 in Mice Leads to Altered Gene Expression in Inflammatory and Metabolic Pathways
Meghadri SH, Martinez-Delgado B, Ostermann L, Gomez-Mariano G, Perez-Luz S, Tumpara S, Wrenger S, DeLuca DS, Maus UA, Welte T, Janciauskiene S. Loss of Serpina1 in Mice Leads to Altered Gene Expression in Inflammatory and Metabolic Pathways. Int J Mol Sci. 2022 Sep 9;23(18).
PUBMED DOIMice inflammatory responses to inhaled aerosolized LPS: effects of various forms of human alpha1-antitrypsin
Sivaraman K, Wrenger S, Liu B, Schaudien D, Hesse C, Gomez-Mariano G, Perez-Luz S, Sewald K, DeLuca D, Wurm MJ, Pino P, Welte T, Martinez-Delgado B, Janciauskiene S. Mice inflammatory responses to inhaled aerosolized LPS: effects of various forms of human alpha1-antitrypsin. J Leukoc Biol. 2023 Jan 10;113(1):58-70.
PUBMED DOIInformación adicional
La Unidad de Modelos y Mecanismos tiene como objetivo la generación de modelos celulares para facilitar el diagnóstico de enfermedades raras complejas y estudiar los mecanismos moleculares responsables de la sintomatología de los pacientes. Entre otros modelos generamos células madre pluripotentes inducidas, también conocidas como iPSCs, a partir de células somáticas de pacientes con enfermedades raras que posteriormente diferenciamos a tipos celulares relevantes para estudiar la enfermedad, como por ejemplo neuronas. Nuestra unidad se centra especialmente (aunque no exclusivamente) en el estudio de enfermedades raras con base epigenética y en el uso de perfiles epigenéticos para mejorar el diagnóstico.